XXXX of the pancreas. A clinicopathologic study, including DNA flow cytometry.

@entity1 @entity788 @entity2007 @entity146 @entity5 @entity8940 @entity12679 @entity7157
OBJECTIVE: To review the classification, clinical behavior, and appropriate therapy for @entity788 . We examined @entity1 demographics, clinical parameters, preoperative imaging modalities, histologic findings, and @entity5 DNA content to determine which best predict outcome. DESIGN: Case series and survey of pathologic specimens. SETTING: Tertiary care center. @entity1 : Twenty-two @entity1 with @entity788 treated at affiliates of Northwestern University Medical School, Chicago, Ill. MAIN OUTCOME MEASURES: Predictive value of preoperative testing, @entity5 DNA content, @entity1 survival. RESULTS: In 20 @entity1 undergoing computed tomographic scan, the @entity5 was visualized in every case. All other imaging studies evaluated were less likely to demonstrate the lesion. Eight of 10 @entity1 with @entity12679 were alive with no evidence of disease at the time of this report; one @entity1 was alive with local recurrence, and a second @entity1 had died of unrelated causes. All @entity1 with @entity8940 were alive with no evidence of disease. Three of seven @entity1 with @entity7157 had @entity2007 , high S-phase @entity5 , and one had a diploid, high S-phase @entity5 ; all four died (mean survival, 4.8 months). Two @entity1 with @entity7157 had diploid, low S-phase @entity5 ; both were long-term survivors but died of their disease at 8.6 and 9.3 years. CONCLUSIONS: (1) Computed tomographic scan is the most valuable diagnostic imaging study for preoperative evaluation of these @entity1 . (2) Precise preoperative determination of @entity5 type is not possible. (3) DNA flow cytometry may help identify @entity1 with @entity146 who may benefit from adjuvant chemoradiation.
